Lactoferrin (17-41) (acetate)(Synonyms: Lactoferricin B acetate Lfcin B acetate)

Lactoferrin (17-41) (acetate);(Synonyms: Lactoferricin B acetate; Lfcin B acetate) 纯度: 99.08%

Lactoferrin 17-41 (Lactoferricin B) acetate 对应于牛乳铁蛋白的残基 17-41,对革兰氏阳性和革兰氏阴性细菌、病毒、原生动物和真菌等多种微生物具有抗菌活性。Lactoferrin 17-41 acetate 具有抗肿瘤活性。

Lactoferrin (17-41) (acetate)amp;;(Synonyms: Lactoferricin B acetate; Lfcin B acetate)

Lactoferrin (17-41) (acetate) Chemical Structure

规格 价格 是否有货 数量
5 mg ¥1200 In-stock
10 mg ¥2000 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Lactoferrin (17-41) (acetate) 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Apoptosis Compound Library
  • Anti-Cancer Compound Library
  • Antifungal Compound Library
  • Antibacterial Compound Library
  • Peptide Library

生物活性

Lactoferrin 17-41 (Lactoferricin B) acetate, a peptide corresponding to residues 17-41 of bovine lactoferrin, has antimicrobial activity against a wide range of microorganisms, including Gram-positive and Gramnegative bacteria, viruses, protozoa, and fungi. Lactoferrin 17-41 acetate has antitumor activities[1][2].

体外研究
(In Vitro)

Lactoferrin 17-41 (Lactoferricin B) acetate has an MIC of 30 μg/ml against E. coli ATCC 25922[1].
Lactoferrin 17-41 acetate significantly stimulates apoptosis of HT-29 cells and displays cytotoxic activity on HT-29 cells[2].
Lactoferrin 17-41 acetate variously regulats transcription of genes involved in the p53 signaling pathway, such as PMAIP-1, TP5313, and SFN[2].
Lactoferrin 17-41 acetate can bind LPS from Gram-negative bacteria and that it can inhibit LPS induced cytokine response in human monocytic cells[1][3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: HT-29 cells
Concentration: 50, 100, 200, 400, 800 or 1000 µg/mL
Incubation Time: 4, 12, 24 or 48 hours
Result: More effective at inducing apoptosis at 400 µg/mL. Higher toxicity is shown at 800 µg/mL.

分子量

3183.82

Formula

C143H226N46O33S3

Sequence

Phe-Lys-Cys-Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys-Leu-Gly-Ala-Pro-Ser-Ile-Thr-Cys-Val-Arg-Arg-Ala-Phe (Disulfide bridge: Cys3-Cys20)

Sequence Shortening

FKCRRWQWRMKKLGAPSITCVRRAF (Disulfide bridge: Cys3-Cys20)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture and light)

溶解性数据
In Vitro:;

DMSO : 20 mg/mL (6.28 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.3141 mL 1.5704 mL 3.1409 mL
5 mM 0.0628 mL 0.3141 mL 0.6282 mL
10 mM

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2 mg/mL (0.63 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (0.63 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2 mg/mL (0.63 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (0.63 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2 mg/mL (0.63 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (0.63 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Samuelsen Ø, et al. Anti-complement effects of lactoferrin-derived peptides. FEMS Immunol Med Microbiol. 2004 Jun 1;41(2):141-8.

    [2]. Jiang R, et al. Bovine lactoferrin and lactoferricin exert antitumor activities on human colorectal cancer cells(HT-29) by activating various signaling pathways. Biochem Cell Biol. 2017 Feb;95(1):99-109.

    [3]. Latorre D, et al. Reciprocal interactions between lactoferrin and bacterial endotoxins and their role in the regulation of the immune response. Toxins (Basel). 2010;2(1):54‐68.